Taking an Aggressive Approach to the Management of Chronic Urticaria
PROGRAM DESCRIPTION Despite a substantial body of evidence indicating that approximately half of patients with chronic idiopathic urticaria (CIU) are refractory to and obtain little or no benefit from even ...
PROGRAM DESCRIPTION
Despite a substantial body of evidence indicating that approximately half of patients with chronic idiopathic urticaria (CIU) are refractory to and obtain little or no benefit from even up-dosing of antihistamines, many clinicians do not move aggressively to next-phase treatment options or consider the mechanistic and target-specific properties and efficacy of guideline-recommended alternative agents. This Specialty House Call focuses on the importance of early use of validated assessment tools to gauge the degree of severity and the role of the full range of currently available agents—including corticosteroids, cyclosporine, and omalizumab—for patients with refractory CIU (also known as chronic spontaneous urticaria). The activity is notable for the inclusion of video segments of an actual CIU patient who shared her views on how CIU affected her quality of life, treatment strategies over time, and the status of her disease today.
EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be better able to:Analyze the safety and efficacy of available and emerging immunobiologic therapies for refractory chronic urticariaUtilize standardized tools to assess disease severity, response to treatment, and quality of life in patients who suffer from urticaria
Read more about this
Write the first review
Join now
to leave a review or read peer reviews!
Resource tags
Show all tags
